D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy

[1]  Y. Agid,et al.  Does levodopa aggravate Parkinson's disease? , 1988, Neurology.

[2]  Y. Agid,et al.  [3H]Dihydrotetrabenazine, a New In Vitro Monoaminergic Probe for Human Brain , 1988, Journal of neurochemistry.

[3]  Y. Agid,et al.  Dopamine D‐1 Receptor and Cyclic AMP‐Dependent Phosphorylation in Parkinson's Disease , 1987, Journal of neurochemistry.

[4]  J. Korf,et al.  Tracing of dopamine receptors in hemiparkinsonism with positron emission tomography (PET) , 1987, Journal of the Neurological Sciences.

[5]  I. Kilpatrick,et al.  Behavioural role of dopamine D1 receptors in the reserpine-treated mouse , 1987, Neuroscience.

[6]  T. Chase,et al.  D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. , 1987, Science.

[7]  M. Savasta,et al.  Denervation supersensitivity of striatal D2 dopamine receptors is restricted to the ventro- and dorsolateral regions of the striatum , 1987, Neuroscience Letters.

[8]  M. Starr,et al.  Topography of dopamine behaviours mediated by D1 and D2 receptors revealed by intrastriatal injection of SKF 38393, lisuride and apomorphine in rats with a unilateral 6-hydroxydopamine-induced lesion , 1987, Neuroscience.

[9]  G. Di Chiara,et al.  Behavioural expression of D-1 receptor supersensitivity depends on previous stimulation of D-2 receptors. , 1987, Life sciences.

[10]  J. H. Carlson,et al.  Stimulation of both D1 and D2 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: a neurophysiological study , 1987, Brain Research.

[11]  A. Graybiel,et al.  Differences in tyrosine hydroxylase-like immunoreactivity characterize the mesostriatal innervation of striosomes and extrastriosomal matrix at maturity. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Y. Agid,et al.  Pitfalls in membrane binding sites studies in post-mortem human brain. , 1987, Journal of receptor research.

[13]  D. Fage,et al.  Opposing effects of D-1 and D-2 receptor antagonists on acetylcholine levels in the rat striatum. , 1986, European journal of pharmacology.

[14]  G. Di Chiara,et al.  D-1 receptor supersensitivity in the rat striatum after unilateral 6-hydroxydopamine lesions. , 1986, European journal of pharmacology.

[15]  B. Scatton,et al.  Autoradiographic localization and quantification of dopamine D2 receptors in normal human brain with [3H]N-n-propylnorapomorphine , 1986, Brain Research.

[16]  Philip Seeman,et al.  Dopamine D2 receptor density remains constant in treated Parkinson's disease , 1986, Annals of neurology.

[17]  Y. Agid,et al.  Loss of Striatal [76Br]Bromospiperone Binding Sites Demonstrated by Positron Tomography in Progressive Supranuclear Palsy , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  J. Rinne,et al.  Dopamine D-1 receptors in the parkinsonian brain , 1985, Brain Research.

[19]  M. Traub,et al.  The effects of chronic bromocriptine treatment on behaviour and dopamine receptor binding in the rat striatum. , 1985, European journal of pharmacology.

[20]  E. Hirsch,et al.  Dopaminergic and cholinergic lesions in progressive supranuclear palsy , 1985, Annals of neurology.

[21]  G. Reynolds,et al.  [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. , 1985, European journal of pharmacology.

[22]  Y. Agid,et al.  Binding of [3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects. , 1985, European journal of pharmacology.

[23]  M. Zigmond,et al.  Chronic neuroleptic treatment increases D-2 but not D-1 receptors in rat striatum. , 1985, European journal of pharmacology.

[24]  C. Altar,et al.  Computer imaging and analysis of dopamine (D2) and serotonin (S2) binding sites in rat basal ganglia or neocortex labeled by [3H]spiroperidol. , 1985, The Journal of pharmacology and experimental therapeutics.

[25]  S. Fahn,et al.  Chronic levodopa or pergolide administration induces down‐regulation of dopamine receptors in denervated striatum , 1984, Neurology.

[26]  Y. Agid,et al.  [3H]spiperone binding in the nigrostriatal system in human brain. , 1984, European journal of pharmacology.

[27]  Y Agid,et al.  [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. , 1984, European journal of pharmacology.

[28]  J. C. Stoof,et al.  Stimulation of D2-dopamine receptors in rat neostriatum inhibits the release of acetylcholine and dopamine but does not affect the release of gamma-aminobutyric acid, glutamate or serotonin. , 1982, European journal of pharmacology.

[29]  Y. Agid,et al.  Micro topography of Tyrosine Hydroxylase, Glutamic Acid Decarboxylase, and Choline Acetyltransferase in the Substantia Nigra and Ventral Tegmental Area of Control and Parkinsonian Brains , 1981, Journal of neurochemistry.

[30]  U. Rinne.  Brain neurotransmitter receptors in Parkinson's disease , 1981 .

[31]  P. Seeman.  Brain dopamine receptors. , 1980, Pharmacological reviews.

[32]  R. Wurtman,et al.  Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization , 1980, Brain Research.

[33]  P. Seeman,et al.  Abnormal neuroleptic/dopamine receptors in schizophrenia. , 1980, Advances in biochemical psychopharmacology.

[34]  R. Bannister,et al.  Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's disease , 1979, Journal of the Neurological Sciences.

[35]  P. Seeman,et al.  Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats. , 1979, Life sciences.

[36]  T. Nagatsu,et al.  Dopamine-stimulated adenylate cyclase activity in the human brain: changes in Parkinsonism. , 1978, Biochemical medicine.

[37]  O. Hornykiewicz,et al.  Receptor basis for dopaminergic supersensitivity in Parkinson's disease , 1978, Nature.

[38]  K. Jellinger,et al.  Dopamine-sensitive adenylate cyclase activity in the caudate nucleus and adrenal medulla in Parkinson's disease and in liver cirrhosis. , 1978, Journal of neural transmission. Supplementum.

[39]  J. Fields,et al.  Neurotransmitter receptor alterations in Parkinson's disease. , 1977, Life sciences.

[40]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[41]  F. Fonnum,et al.  Radiochemical micro assays for the determination of choline acetyltransferase and acetylcholinesterase activities. , 1969, The Biochemical journal.

[42]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.